(Q57207899)

English

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

based on heuristic

inferred from title

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Pierre Laurent-Puig

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Julien Taieb

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Enrico Mini

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Fabien Subtil

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jean-Luc Van Laethem

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Josef Thaler

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

John Bridgewater

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Lone Nørgård Petersen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Laurence Collette

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Eric Van Cutsem

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Philippe Rougier

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ramon Salazar

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Laurent Bedenne

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jean-François Emile

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Come Lepage

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Josep Tabernero

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Gunnar Folprecht

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PETACC-8 Study Investigators

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

11 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

862-873

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Review: Biological relevance of disseminated tumor cells in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970227-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70227-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24928083%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57207899&oldid=1997420995"